EARNING RECAP

Vertex Pharmaceuticals Inc

#VRTX 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q3 adjusted EPS $1.09 vs $1.02 $784.54M vs $790.91M +1.55% ($165.61 closing) $167.00 $153.00 FY18 revenue view of $2.9B-$3B
Q2 94c est. 75c $750M est. $680.98M -.53% ($175.87 closing) $178.85 $169.33 raises Fy18 revenue view to $2.9B - $3.05B from $2.65B- $2.8B est. $2.81B
Q1 adjusted 76c est. 62c $638M est. $617.59M -1.74% ($156.05 closing) $159.05 $153.33 Fy18 product revenue $2.65B-$2.80B est. $2.78B, initiates P3 studies of VX-445, Tezacaftor &Ivacaftor
#VRTX 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 61c est. 53c $651.36M est. $594.72M +3.74% $174.96 $163.17 VX-659 & VX-445 to advance to Phase 3
Q3 non GAAP 53c vs. 31c $578.2 vs. $520.13 -2.07% ($143.76 closing) $147.43 $139.05 raises '10 CF productrevenue $2.10B-$2.15B from $1.87B-$2.10B
Q2 Adjusted EPS 39c vs 35c $544.14m vs $487.49m -4.42% ($156.19 closing) $163.32 $153.50 CF net product evenues were $514.0M. ORKAMBI $324.40m. Kalyedco $189.6m. -0.26% to $163.00
Q1 41c vs 40c Total rev $714.7M. Product $480.60m vs $510.60M +0.75% ($118.30 closing) $120.50 $115.45 raises FY17 KALYDECO sales to $710M-$730M from $690M-$710M. Stock +1.66% AH at $119.37

TradersFish provides FREE valuable, unique, and simplified stock market data. Your donation will help us further expand our operations. Thank you for your contribution!


Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.